- Remaining interest to be held for the long-term -

Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the venture capital company 3i has, in the course of the current restructuring of its portfolio, reduced its interest in Evotec AG from 7.176% (status May 2005; corresponding to 5.98% after the 24 June 2005 capital increase) to 4.991% through the sale of shares at the stock exchange during the past weeks. In addition, a further 570,000 Evotec shares were sold off-market yesterday.
 
3i had received all the shares now sold in exchange for its shares in Oxford Asymmetry International plc (OAI) in the wake of the merger of OAI and Evotec in 2000.
 
3i now holds an interest in Evotec of 4.070% resulting from the takeover of Evotec Neurosciences GmbH through Evotec earlier this year. The venture capital company regards this remaining interest in the combined company as a long-term strategic investment.

Evotec AG
Anne Hennecke
+49 40 56081286
anne.hennecke@evotec.com
Evotec AG
Anne Hennecke
+49 40 56081286
anne.hennecke@evotec.com